Philip Reilly is our Interim Chief Medical Officer and a Venture Partner at Third Rock Ventures. He is a highly respected clinical geneticist with an extensive track record in launching and building companies that seek to develop new therapies for rare genetic disorders. Dr. Reilly joined Third Rock in 2008 to focus on discovering, launching and building transformational companies dedicated to breakthrough treatments for rare diseases. Dr. Reilly is currently a Trustee of Cornell University and is on the Board of Overseers of Weill Cornell Medical College. Prior to joining Third Rock, he was the CEO and Chairman of Interleukin Genetics, and before that, he was the Executive Director of the Eunice Kennedy Shriver Center for Mental Retardation. He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals as well as several books about clinical genetics. Dr. Reilly has held teaching positions at Tufts University School of Medicine and Harvard Medical School. He serves on the scientific advisory board of bluebird bio and is a board observer at Edimer Pharmaceuticals. Dr. Reilly holds an M.D. from Yale University, a J.D. from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.